ImmunoPrecise Antibodies (STU:TQB) Cash Flow from Financing : €11.04 Mil (TTM As of Jan. 2025)

ImmunoPrecise Antibodies Cash Flow from Financing Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
Cash Flow from Financing		Get a 7-Day Free Trial					0.11	29.03	2.11	-0.42	0.70

ImmunoPrecise Antibodies Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Cash Flow from Financing	Get a 7-Day Free Trial															0.42	0.77	1.81	1.38	7.08

ImmunoPrecise Antibodies Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

ImmunoPrecise Antibodies's Cash from Financing for the fiscal year that ended in Apr. 2024 is calculated as:

ImmunoPrecise Antibodies's Cash from Financing for the quarter that ended in Jan. 2025 is:

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunoPrecise Antibodies  (STU:TQB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

ImmunoPrecise Antibodies's issuance of stock for the three months ended in Jan. 2025 was €7.19 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

ImmunoPrecise Antibodies's repurchase of stock for the three months ended in Jan. 2025 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

ImmunoPrecise Antibodies's net issuance of debt for the three months ended in Jan. 2025 was €-0.11 Mil. ImmunoPrecise Antibodies spent €0.11 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

ImmunoPrecise Antibodies's net issuance of preferred for the three months ended in Jan. 2025 was €0.00 Mil. ImmunoPrecise Antibodies paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

ImmunoPrecise Antibodies's cash flow for dividends for the three months ended in Jan. 2025 was €0.00 Mil. ImmunoPrecise Antibodies received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

ImmunoPrecise Antibodies's other financing for the three months ended in Jan. 2025 was €0.00 Mil. ImmunoPrecise Antibodies received €0.00 Mil on other financial activities.

ImmunoPrecise Antibodies Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description